Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis

Multiple Myeloma (MM)

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Blood Cancer J

Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C, Chakraborty R

doi: 10.1038/s41408-024-01003-z

Multiple Myeloma (MM)

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Blood

Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, Cavo M, Martinez Chamorro C, Nooka AK, Martin TG, Karlin L, Leleu X, Bahlis NJ, Besemer B, Pei L, Stein S, Wang Lin SX, Trancucci D, Verona R, Girgis S, Miao X, Uhlar C, Chastain K, Garfall A

doi: 10.1182/blood.2023023616

Multiple Myeloma (MM)

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry

Br J Haematol

Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, Touzeau C, Leleu X, Moya N, Harel S, Perrot A, Bories P, Vincent L, Lamure S, Mohty M, Malard F, Manier S, Yakoub-Agha I, Schiano De Colella JM, Brisou G, Talbot A, Decaux O, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Moreau P, Arnulf B, Intergroupe Francophone du Myélome

doi: 10.1111/bjh.19505

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence

Lung Cancer

Nadal E, Rifi N, Kane S, Mbacke S, Starkman L, Suero B, Le H, Samjoo IA

doi: 10.1016/j.lungcan.2024.107816

Multiple Myeloma (MM)

Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group

Am J Hematol

Katodritou E, Dalampira D, Delimpasi S, Ntanasis-Stathopoulos I, Karaolidou F, Gkioka AI, Labropoulou V, Spanoudakis E, Triantafyllou T, Kotsopoulou M, Michalis E, Vadikolia C, Papadopoulou T, Sevastoudi A, Michael M, Daiou A, Pentidou A, Kostopoulos I, Palaska V, Gavriatopoulou M, Kyrtsonis MC, Verrou E, Kastritis E, Dimopoulos MA, Terpos E

doi: 10.1002/ajh.27425

Multiple Myeloma (MM)

Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study

Leuk Lymphoma

Knauf W, Uhlig J, von der Heyde E, Losem C, Ammon A, Nusch A, Schlag R, Schulz H, Janssen J, Welslau M, Wilop S, Vannier C, Siebenbach HU, Serrer L, Schuch A, Woerner SM, Engelhardt M, Potthoff K

doi: 10.1080/10428194.2024.2436034

SPECIAL REPORT

Breast Cancer

Results of TRODELVY^® real-world data

Multiple Myeloma (MM)

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study

Br J Haematol

Zhou X, Wagner V, Scheller L, Stanojkovska E, Riedhammer C, Xiao X, Steinhardt MJ, Vogt C, Nerreter S, Eisele F, John M, Munawar U, Kadel SK, Mersi J, Ruckdeschel A, Schimanski S, Haertle L, Waldschmidt JM, Han S, Topp M, Duell J, Einsele H, Riedel A, Kortüm KM, Rasche L

doi: 10.1111/bjh.19515

Multiple Myeloma (MM)

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence

Br J Haematol

Hartley-Brown MA, Weisel K, Bitetti J, Carter JA, McNamara S, Purser M, Palumbo A, Richardson PG

doi: 10.1111/bjh.19627

Related content

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry

Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence

Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group

Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study

Results of TRODELVY® real-world data

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence

Results of TRODELVY^® real-world data